We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investor malaise stalks UK, European biotech.
- Authors
Mitchell, Peter
- Abstract
The article provides information on the status and conditions on the stock market in Europe. According to the author, the European biotech sector has lost significant value compared to the U.S. industry and the UK industry is the weakest performer in Europe. He added that a London-based biotech analyst at merchant bank Lehman Brothers Peter Welford has stated that the European biotech stock prices fell by 23% on average. Meanwhile, the Thomson Financial figures has shown that the UK biotech industry has fell by nearly 40%, while the weighted biotech shares fell by only 8%.
- Subjects
EUROPE; INVESTORS; BIOTECHNOLOGY; BIOTECHNOLOGY industries; ECONOMIC development; STOCK exchanges; STOCK price indexes; STOCK prices; ECONOMIC conditions in Europe
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 3, p256
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0308-256c